EGRX News and Press, Eagle Pharmaceuticals Inc. From 08/01/23

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. ...

2023-07-31 07:28:43 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) has raised its Adjusted non-GAAP EPS and Adjusted non-GAAP EBITDA guidance for FY2023. The stock increased 3% during Monday's premarket hours. The pharmaceutical company now sees adjusted EPS in the ran...

-- FY 2023 Adjusted non-GAAP earnings per share now expected to be $4.40 - $4.70 1 -- -- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million 1 -- -- FY 2023 Adjusted non-GAAP R&D expense is reiterated at $41.0-$45.0 million 1 -- -- FY 2023 Adjusted non-GAAP...

Despite the availability of antibiotics, the death rate from pneumonia in the U.S. has seen little improvement in the past half century 1 – CAL02 is a unique therapeutic agent that works differently from antibiotics, disarming an infectious pathogen’s virulence ...

2023-06-15 13:59:13 ET Eagle Pharmaceuticals ( NASDAQ: EGRX ) reaffirmed its 2023 financial forecast on Thursday and issued a sales update for its drugs Barhemsys, Byfavo and Pemfexy. Eagle said that for the quarter to date, its recently acquired drugs Barhemsys and Byfavo have ...

WOODCLIFF LAKE, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and reiterated its 2023 financial guidance. “As we approach midyear 2023, our business remains st...

– Company believes CAL02 is a new chemical entity (NCE), which would result in five years of marketing exclusivity upon approval or three years without NCE designation; total potential of eight or ten years of exclusivity – – Eagle has approved patents ru...

Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 Palo Alto Networks Set to S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK , June 2, 2023 /PRNewswire/ -- S&P Dow...

WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that two abstracts were accepted for presentation at the Society for Academic Emergency Medicine (SAEM) Annual Meeting, being he...

2023-05-09 12:59:04 ET Eagle Pharmaceuticals, Inc. ( EGRX ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 am ET Corporate Participants Lisa Wilson - Investor Relations Scott Tarriff - President and Chief Executive Officer Brian Cahill - Chief Financial Of...